Taylor Frigon Capital Management LLC Has $2.26 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Taylor Frigon Capital Management LLC lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 10.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 29,060 shares of the medical device company’s stock after selling 3,494 shares during the period. Taylor Frigon Capital Management LLC’s holdings in DexCom were worth $2,260,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in DXCM. Versant Capital Management Inc acquired a new stake in DexCom in the 4th quarter valued at $25,000. Heck Capital Advisors LLC bought a new position in shares of DexCom in the 4th quarter valued at about $38,000. Midwest Capital Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter valued at about $54,000. RPg Family Wealth Advisory LLC bought a new stake in DexCom during the third quarter worth about $57,000. Finally, Rothschild Investment LLC raised its holdings in DexCom by 250.5% during the fourth quarter. Rothschild Investment LLC now owns 750 shares of the medical device company’s stock worth $58,000 after acquiring an additional 536 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling

In other news, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,083 shares of company stock valued at $3,309,794. 0.30% of the stock is owned by company insiders.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $89.91 on Thursday. The firm has a market cap of $35.13 billion, a P/E ratio of 62.87, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14. The business’s 50 day moving average is $84.29 and its 200-day moving average is $76.47. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have weighed in on DXCM. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Wells Fargo & Company upped their price target on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Citigroup lifted their price objective on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and upped their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $99.06.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.